Her-2/neu and breast cancer

Stamatina Kaptain, Lee K. Tan, Beiyun Chen

Research output: Contribution to journalReview articlepeer-review

161 Scopus citations


Breast cancer is the most common malignancy in women in the United States in the year 2000. The proto-oncogene Her-2/neu (c-erb-B2) has become an increasingly important prognostic and predictive factor in breast cancer. Overexpression/amplification of the Her-2/neu has been associated with a worse outcome in patients with breast cancer. Herceptin, a "humanized" murine monoclonal antibody directed against the extracellular domain of the Her-2/neu protein, is being used to treat breast cancer that overexpresses Her-2/neu. The status of Her-2/neu in the tumor has become a critical factor in the management strategy of a breast cancer patient. The objective of this article is to provide a comprehensive review of all aspects of Her-2/neu in breast cancer, including biology, prognostic and predictive value, targeted Herceptin therapy, and the laboratory testing of Her-2/neu.

Original languageEnglish (US)
Pages (from-to)139-152
Number of pages14
JournalDiagnostic Molecular Pathology
Issue number3
StatePublished - 2001


  • Breast carcinoma
  • C-erb-B2
  • Her-2/neu
  • Herceptin
  • Trastuzumab

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Her-2/neu and breast cancer'. Together they form a unique fingerprint.

Cite this